Lipidated incretin peptide

Tirzepatide

Name: Tirzepatide
Price: 69 USD

Tirzepatide is investigated as a dual GIP and GLP-1 receptor agonist in metabolic research, including translational and clinical studies.

BLOPEP vial — representative image — Representative image

Quantity per vial

Select variantCompare prices and choose a variant to set the quantity and add it to your quote.

Subtotal excludes freight and taxes. Availability and final terms are confirmed in the quote. Commercial and shipping terms

Mechanism and findings →

Mechanism and findings

Mixed · Study formulation · Cell/animal experiments and phase 1 human cohorts

Dual receptor activity

LY3298176 activated GIP and GLP-1 signaling; early clinical cohorts assessed metabolic endpoints and reported gastrointestinal adverse events.

Coskun et al., 2018 →

Literature findings; refer to the model and formulation studied.

Mechanism of action

Tirzepatide — lipidated incretin peptide. The literature identity must be matched to the documented chemical form and composition of the supplied material.

Cell assays characterized GIP and GLP-1 receptor activation by LY3298176. Mouse experiments examined glucose-dependent insulin secretion and metabolic profiles. Early human work included healthy participants and people with type 2 diabetes, who should not be merged into one population.

GLP-1R / GIPR

Coskun et al., 2018

Studied findings 1

Mixed · Study formulation

Dual receptor activity

Cell/animal experiments and phase 1 human cohorts

LY3298176 activated GIP and GLP-1 signaling; early clinical cohorts assessed metabolic endpoints and reported gastrointestinal adverse events.

View context

Study design: Original-study abstract; experimental design described in linked source
Sample scope / arm: Not extracted; consult original study
Comparator: See original-study context
Experimental context (not instructions for use): Abstract-level extraction; full methods and tables still require review.
Source section / table / abstract: Abstract

Evidence concerns the studied material and model, not the supplied BLOPEP batch.

Coskun et al., 2018

Sources and studies 1

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A · 2018 · Molecular metabolism
DOI: 10.1016/j.molmet.2018.09.009